uniQure Investors Face April 13 Deadline as Securities Class Action Moves Forward

A new legal notice is drawing attention from investors in uniQure N.V., the biotechnology company listed on Nasdaq under the ticker QURE. According to an announcement released on March 31, 2026, plaintiffs’ law firm Berger Montague PC says a securities class action lawsuit has been filed on behalf of investors who bought or otherwise acquired uniQure securities between September 24, 2025 and October 31, 2025. The firm says affected investors have until April 13, 2026 to ask the court to appoint them as lead plaintiff in the case.

What the lawsuit is about

The case centers on allegations that uniQure and certain defendants gave investors an incomplete or misleading picture of the company’s regulatory progress for AMT-130, an experimental gene therapy being developed for Huntington’s disease. uniQure, which is headquartered in Amsterdam, the Netherlands, has focused much of its recent attention on gene therapies for severe diseases, and AMT-130 has been one of its most closely watched programs.

According to the complaint described in the notice, the lawsuit alleges that during the class period the company failed to properly disclose key facts tied to the design of its pivotal study for AMT-130. More specifically, the complaint claims the study design had not been fully approved by the U.S. Food and Drug Administration, including the company’s approach of comparing treatment results with the ENROLL-HD external historical data set. The complaint also alleges that the company downplayed the risk that it would need to delay its planned Biologics License Application (BLA) timeline in order to conduct additional studies.

Why investors are paying attention

The legal notice points to a major market reaction that followed a company disclosure made on November 3, 2025. On that date, uniQure disclosed that the FDA did not agree that the company’s Phase I/II data could serve as the primary evidence for a BLA submission for AMT-130. The company also said the timing of any BLA filing had become unclear.

That update had an immediate impact on the stock. The notice says uniQure shares fell by more than 49%, dropping from a closing price of $67.69 per share on October 31, 2025 to $34.29 per share on November 3, 2025, which was the next trading day. For many investors, that sharp decline is at the heart of the lawsuit, because the case argues that the market was reacting to previously undisclosed or misrepresented information about the company’s regulatory path and development timeline.

Why AMT-130 matters so much

AMT-130 is an important program for uniQure because Huntington’s disease is a serious inherited brain disorder with limited treatment options. Gene therapy programs in this area often attract strong investor interest because they can represent both significant medical hope and major commercial opportunity. That also means the market tends to react quickly to any change in regulatory expectations, study design, or timelines.

In uniQure’s case, expectations around AMT-130 appear to have been especially significant. Investors watching the company were not just looking at early-stage science. They were also watching whether the treatment could move efficiently toward a regulatory submission. When the FDA’s position appeared less supportive than some investors may have expected, the reaction was dramatic. The lawsuit now seeks to examine whether that risk should have been communicated more clearly to the market earlier. This summary reflects allegations in the complaint described by Berger Montague and not a court finding of wrongdoing.

Who may be included in the proposed class

Based on the legal notice, the proposed class includes investors who purchased or otherwise acquired uniQure securities during the period from September 24, 2025 through October 31, 2025. People who fall within that group may be eligible to participate in the class action, depending on how the case develops and how the court defines the class.

The announcement also highlights the role of a lead plaintiff. In securities class actions, the lead plaintiff is typically an investor or small group of investors who represents the interests of the broader class during litigation. Being appointed lead plaintiff can involve working with counsel, reviewing filings, and helping direct the case on behalf of all similarly situated investors.

Important deadline for investors

The most important date in the notice is April 13, 2026. That is the deadline Berger Montague says investors must meet if they want to seek appointment as lead plaintiff. Missing that deadline does not necessarily mean an investor loses all rights to share in a future recovery if the case succeeds, but it does mean they may lose the opportunity to serve in that leadership role.

Berger Montague’s role in the case

Berger Montague describes itself as a national plaintiffs’ law firm with a long history in complex civil litigation, class actions, and mass tort matters. In the same notice, the firm says it has recovered more than $50 billion for clients and represented classes over more than 55 years of practice. The release also states that the firm recorded more than $2.4 billion in 2025 post-trial judgments alone.

For investors seeking information about the uniQure matter, the notice lists two contacts at the firm: Andrew Abramowitz and Caitlin Adorni. Their contact details were provided in the original release for investors who want to discuss their legal rights or learn more about the case.

Market and legal significance

This case is another example of how closely investors, regulators, and the legal community watch public statements made by biotechnology companies. In the biotech sector, timelines tied to clinical development and FDA engagement can have a major influence on valuation. Even small changes in how a company describes regulatory feedback can move a stock sharply if investors believe those changes affect approval prospects, commercialization timing, or future fundraising needs.

That is why lawsuits like this often focus on whether company disclosures were complete, timely, and accurate. In this situation, the core legal issue appears to be whether uniQure’s public statements during the class period gave investors a fair understanding of the FDA’s position on the use of Phase I/II data and on the broader design of the AMT-130 pivotal study. The lawsuit allegations remain claims at this stage, and the court process will determine how the matter proceeds.

What investors should take away

For current and former uniQure investors, the key point is simple: this is a deadline-driven legal development tied to a major stock decline and to disputed disclosures surrounding one of the company’s most important drug programs. Investors who bought shares during the specified period and believe they were affected should pay close attention to the April 13, 2026 lead plaintiff deadline announced in the release.

At the same time, the broader story is about more than one court filing. It reflects the pressure biotech companies face when balancing scientific optimism, regulatory uncertainty, and investor expectations. For a company developing a high-profile gene therapy like AMT-130, any gap between market expectations and regulatory reality can quickly become both a financial and legal issue.

Bottom line

uniQure is now facing heightened scrutiny after a steep stock drop followed its November 2025 disclosure about FDA feedback on AMT-130. Berger Montague’s March 31, 2026 announcement puts investors on notice that a class action is already underway and that those wishing to seek lead plaintiff status must act by April 13, 2026. The case will likely be watched closely not only by shareholders, but also by biotech investors tracking how companies communicate regulatory risk in fast-moving drug development programs.

#SlimScan #GrowthStocks #CANSLIM